|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
Pharmacokinetics, Prandial Glucose Control, and Safety of Insulin Glulisine in Children and Adolescents With Type 1 Diabetes
1 Kinderkrankenhaus auf der Bult, Hannover, Germany
2 Aventis Pharma Deutschland, Frankfurt/Main, Germany
3 Profil Institut für Stoffwechselforschung, Neuss, Germany
Address correspondence and reprint requests to Thomas Danne, MD, Kinderkrankenhaus auf der Bult, Diabetes-Zentrum für Kinder und Jugendliche, Janusz-Korczak-Allee 12, 30173 Hannover, Germany. E-mail: danne{at}hka.de
OBJECTIVE—The aim of this study was to investigate the pharmacokinetics, postprandial blood glucose excursions, and safety of insulin glulisine as compared with regular human insulin (RHI), both administered immediately before meals in pediatric patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS—A total of 10 children (aged 5–11 years) and 10 adolescents (aged 12–17 years) were enrolled in a randomized, single-center, single-dose, double-blind, cross-over study. The blood glucose of fasting patients was stabilized with intravenous insulin, following which patients received 0.15 IU/kg of subcutaneously injected insulin glulisine or RHI 2 min before a weight-adjusted standardized liquid meal.
RESULTS—For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 µIU/ml, P < 0.05) and initial insulin concentrations (insulin [area under the curve] AUC0–2h 5,232 vs. 2,994 µIU · min–1 · ml–1, P < 0.05; data are geometric means) were higher after insulin glulisine than RHI. Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P < 0.05) were shorter with insulin glulisine versus RHI. Postprandial glucose excursions after insulin glulisine were lower than after RHI (glucose AUC0–6h 641 vs. 801 mg · h–1 · dl–1, P < 0.05). The pharmacokinetic profile for insulin glulisine was similar for children and adolescents, whereas the pharmacokinetic profile for RHI demonstrated a 64% higher concentration in adolescents. Insulin glulisine was safe and well tolerated.
CONCLUSIONS—The rapid-acting properties of insulin glulisine that have been previously demonstrated in adults are also observed in children and adolescents with type 1 diabetes. Further, these initial data indicate that insulin glulisine is safe and well tolerated in this patient population.
Abbreviations: AUC, area under the curve • MRT, mean residence time • RHI, regular human insulin
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  K. L. Swan, S. A. Weinzimer, J. D. Dziura, G. M. Steil, G. R. Voskanyan, A. T. Steffen, M. L. Martin, and W. V. Tamborlane Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes Diabetes Care, January 1, 2008; 31(1): 44 - 46. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Danne, K. Lange, and O. Kordonouri New developments in the treatment of type 1 diabetes in children Arch. Dis. Child., November 1, 2007; 92(11): 1015 - 1019. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Iltz, P. S. Odegard, S. M. Setter, and R. K. Campbell Update in the Pharmacologic Treatment of Diabetes: Focus on Insulin Detemir, Insulin Glulisine, and Inhaled Dry Powdered Insulin The Diabetes Educator, March 1, 2007; 33(2): 215 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rave, O. Klein, A. D. Frick, and R. H.A. Becker Advantage of Premeal-Injected Insulin Glulisine Compared With Regular Human Insulin in Subjects With Type 1 Diabetes Diabetes Care, August 1, 2006; 29(8): 1812 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |